Impact of antiplatelet therapy on erectile dysfunction following percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction Authors: Joongwon Choi, Chung Un Lee, Hyun Woong Park, Jung Hoon Kim, Yong Seong Lee, Jong-Hwa Ahn, Jin Sin Koh, Min Gyu Kang, Weon Kim, Udaya S. Tantry, Paul A. Gurbel, Jin-Yong Hwang, Young-Hoon Jeong Published: 2026 ABSTRACT Background:Acute myocardial infarction (AMI) is strongly associated with erectile dysfunction (ED). This study evaluated the association between P2Y12 receptor inhibitor type and ED, and factors associated with moderate-to-severe ED in high-risk patients with AMI.MethodsThe HEALING-AMI trial randomized patients with naïve ST-segment elevation myocardial infarction (STEMI) to dual antiplatelet therapy (DAPT) with either ticagrelor or clopidogrel. This substudy included 59 male patients who completed 6 months of DAPT (ticagrelor, n = 30; clopidogrel, n = 29). Erectile function [International Index of Erectile Function-5 (IIEF-5)], Bleeding Academic Research Consortium (BARC) bleeding, and dyspnoea were assessed using standardized questionnaires.ResultsAt 6-month follow-up, moderate-to-severe ED (IIEF-5 ≤ 11) and bleeding episodes (predominantly BARC type 1) were observed in 47.5% and 54.2%, respectively. Compared with clopidogrel, ticagrelor was associated with a lower IIEF-5 score (9.7 ± 8.8 vs. 17.0 ± 7.8, p = 0.002) and lower platelet reactivity [32 ± 67 vs. 146 ± 55 P2Y12 reaction units (PRU) measured by VerifyNow, p < 0.001]. Moderate-to-severe ED was more common in patients treated with ticagrelor than in those treated with clopidogrel (63.3% vs. 31.0%). Bleeding episodes and platelet reactivity were also significantly associated with moderate-to-severe ED. In multivariable analysis, both P2Y12 inhibitor type and bleeding episodes were independently associated with moderate-to-severe ED. After multivariable adjustment, ticagrelor-treated patients who experienced bleeding had an approximately 5.6-fold higher odds of moderate-to-severe ED than clopidogrel-treated patients without bleeding (95% CI 1.052–30.087, p = 0.044).ConclusionsIn male patients with STEMI, moderate-to-severe ED and bleeding episodes were common during DAPT. P2Y12 inhibitor type (ticagrelor vs. clopidogrel) and bleeding episodes were associated with moderate-to-severe ED. Introduction Acute myocardial infarction (AMI) is a life-threatening cardiovascular (CV) event resulting from abrupt coronary artery occlusion that restricts blood flow to the myocardium. AMI is also closely linked to erectile dysfunction (ED), as the two conditions share a common vascular pathophysiology. In high-risk patients with AMI, early intervention and guideline-directed medical therapy (GDMT) have improved clinical outcomes. Dual antiplatelet therapy (DAPT), consisting of aspirin plus a P2Y12 inhibitor, is recommended as standard care after percutaneous coronary intervention (PCI) in patients with AMI (1). Beyond its contribution to coronary occlusion, platelet accumulation within the injured myocardium amplifies local inflammation and promotes left ventricular remodeling (2, 3). Oral adenosine diphosphate (ADP) receptor P2Y12 inhibitors include thienopyridines (ticlopidine, clopidogrel, prasugrel) and ticagrelor. Thienopyridines are prodrugs that irreversibly inhibit P2Y12 via short-lived active metabolites, whereas ticagrelor—an adenosine triphosphate (ATP) analog—directly and reversibly binds P2Y12 as a noncompetitive allosteric antagonist (4). Compared with clopidogrel, ticagrelor provides more potent platelet inhibition. Ticagrelor also exerts pleiotropic effects beyond platelet P2Y12 inhibition that may explain its mortality benefit. These effects are most commonly adenosine-mediated and may modulate vascular tone and microcirculation and influence inflammation and reperfusion biology (5). Contemporary data on the prevalence of ED and its associated factors in this population remain limited, and the impact of different antiplatelet regimens on ED is not well defined. We therefore evaluated the prevalence and factors associated with ED in patients with AMI treated with contemporary procedural strategies and optimal medical therapy. Patients and methods . Design and patients The High Platelet Inhibition with Ticagrelor to Improve Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction (HEALING-AMI) study (NCT02224534) was a prospective, randomized, multicentre trial conducted at 10 academic centers in South Korea (3). Patients were eligible for enrolment if they experienced a first ST-segment elevation myocardial infarction (STEMI) treated with primary PCI and were assigned to a DAPT regimen. The HEALING-AMI–ED substudy evaluated the prevalence and factors associated with ED during medical therapy after primary PCI in male patients with STEMI. This substudy was conducted exclusively at Gyeongsang National University Hospital in Jinju, South Korea (Figure 1). The study protocol was separately approved by the Institutional Review Board of each participating institute (IRB No. 4-2013-0764), and all patients provided written informed consent. Flow diagram of the study. PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction. . Randomization and procedures Patients who met all clinical criteria and provided written informed consent were randomly assigned to receive a 180 mg ticagrelor or 600 mg clopidogrel loading dose (1:1) in the emergency room before the index PCI. All patients received 300 mg of aspirin orally. All PCI procedures were performed according to standard techniques (6). After PCI, patients who received ticagrelor continued ticagrelor 90 mg twice daily, whereas those who received clopidogrel continued clopidogrel 75 mg once daily throughout the study period. Both groups continued to take 100 mg of aspirin daily indefinitely, and all patients were recommended to receive GDMT. During the 6-month follow-up, data regarding clinical status and adverse events were collected at 1, 3, and 6 months. Adherence to pharmacological therapy was also assessed through meticulous interviews, tablet counting, and dedicated questionnaires. . Questionnaire and definitions After completion of 6-month DAPT, the research coordinators collected data using a dedicated questionnaire including ED grade, bleeding episodes, and dyspnoea (Supplementary Table 1). ED was evaluated using the International Index of Erectile Function-5 (IIEF-5) score. Scores range from 5 to 25; higher scores indicate better function. Scores of 22–25 indicate no ED, 17–21 mild ED, 12–16 mild-to-moderate ED, 8–11 moderate ED, and 5–7 severe ED (7). Because patients presented emergently with STEMI and underwent immediate primary PCI, administering the IIEF-5 questionnaire before treatment initiation was not feasible. Erectile function was therefore assessed only at the 6-month follow-up, and the present study focused on erectile function at that time point rather than longitudinal changes from baseline. The Bleeding Academic Research Consortium (BARC) criteria were used to identify bleeding episodes (8, 9). Dyspnoea was categorized using the modified Medical Research Council (mMRC) scale (10). . Laboratory measurements Baseline biochemical assessments were performed using blood samples drawn from an antecubital vein after arrival at the emergency department and at the 6-month follow-up visit in the clinic. Platelet function testing was performed using the VerifyNow PRUTest (Werfen, Barcelona, Spain), with the optical signal reported as P2Y12 reaction units (PRU). Baseline samples were collected before coronary angiography, and follow-up platelet function testing was performed at 1 month, at least 2 hours after DAPT administration. Platelet reactivity was assessed at three prespecified time points—before loading, at hospital discharge, and at the 1-month follow-up—using the VerifyNow P2Y12 assay. The 1-month value was prespecified as the index measure of maintenance-phase platelet reactivity because the preloading value preceded P2Y12 inhibitor exposure, whereas the discharge value could have been influenced by loading-dose effects and the acute phase of myocardial infarction. No additional platelet function testing was performed during subsequent follow-up. . Vascular measurements Vascular function was measured on admission and at the 6-month post-PCI follow-up visit. Using an automated Doppler ultrasound device (VP-1,000; Colin Co., Ltd., Komaki, Japan), the ankle-brachial index (ABI) was measured in each leg within 48 h after PCI. To evaluate arterial stiffness (media function), brachial-ankle pulse wave velocity (baPWV) was measured using the same noninvasive device. Pulse wave velocity was calculated as PWV = ΔD/ΔT, where ΔD is the distance traveled, and ΔT is the transit time. Endothelial function was assessed at the 6 mo follow-up using the EndoPAT system (version 3.0.4; Itamar Medical, Caesarea, Israel) in consenting patients (11). . Endpoints The primary endpoint was the presence of moderate-to-severe erectile dysfunction (IIEF-5 ≤ 11) at the 6-month follow-up. Secondary endpoints were bleeding episodes and dyspnoea. We also evaluated the factors associated with moderate-to-severe ED. Moderate-to-severe ED was defined as an IIEF-5 score of ≤ 11, corresponding to moderate or severe ED (7). . Statistical analysis Continuous variables were reported as mean ± standard deviation or as median (interquartile range [IQR]). The Kolmogorov–Smirnov test was used to assess the normality of continuous variables. Continuous variables were compared using Student's t-test when normally distributed. Categorical variables were reported as numbers and percentages and compared using the chi-square test or Fisher's exact test. Receiver operating characteristic (ROC) curve analysis was performed to determine optimal cutoffs for continuous variables. The ROC curve analysis was performed as an exploratory analysis to identify a potential PRU threshold for subsequent hypothesis-generating analyses. The discriminative performance of PRU was assessed using the area under the curve (AUC) analysis. To evaluate factors associated with moderate-to-severe ED at the 6-month follow-up, variables with p < 0.1 in univariate analysis were entered into multivariable analysis to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Given the limited sample size and number of outcome events, we intentionally restricted the number of variables included in the final models to minimize the risk of overfitting. With 28 outcome events, model 1 estimated three regression coefficients, yielding an events-per-variable (EPV) ratio of 9.3, whereas model 2 estimated four regression coefficients, yielding an EPV of 7.0. A p < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS Statistics for Windows, version 27.0 (IBM Corp., Armonk, NY, USA). Results Initially, 60 male patients with STEMI were enrolled. After one patient in the clopidogrel group withdrew consent, 30 participants in the ticagrelor group and 29 in the clopidogrel group completed the questionnaires and laboratory measurements at the 6-month follow-up (Figure 1). . P2Y12 inhibitor type: baseline characteristics, laboratory measurements, and questionnaires Baseline characteristics did not differ significantly between the groups (Table 1). Baseline laboratory measurements also did not differ between the groups (Table 2). After 6-month treatment, the ticagrelor group had a lower mean glomerular filtration rate (GFR) (83 ± 13 vs. 99 ± 27 ml/min/1.73 m2; p = 0.005) and low-density lipoprotein cholesterol (59 ± 12 vs. 74 ± 21 mg/dl; p = 0.001) than the clopidogrel group. As expected, ticagrelor provided a more potent antiplatelet effect than clopidogrel (32 ± 67 vs. 146 ± 55 PRU; p < 0.001). Table 1Baseline characteristics according to type of P2Y12 inhibitor.CharacteristicsClopidogrel groupTicagrelor groupp value(n = 29)(n = 30)Age, year old52.3 ± 7.953.5 ± 6.60.509Male, n (%)29 (100)30 (100)1.000BMI, kg/m225.7 ± 3.325.3 ± 3.30.690Killip class, n (%)0.638I20 (69.0)19 (63.3)II6 (20.7)7 (23.3)14.6-7.2,-1.3499ptIII3 (10.3)4 (13.3)Risk factors or past history, n (%)Diabetes mellitus4 (13.8)2 (6.7)0.635Hypertension11 (37.9)8 (26.7)0.518Dyslipidemia16 (55.2)13 (43.3)0.516Current smoking21 (72.4)21 (70.0)0.838Chronic kidney disease2 (6.9)1 (3.3)0.976Peripheral artery disease0 (0)1 (3.3)1.000Previous stroke0 (0)1 (3.3)1.000COPD1 (3.4)0 (0.0)0.986Alcohol consumption0.920Non-drinker15 (51.7)17 (56.7)Moderate drinker12 (41.4)12 (40.0)15.6-7.2,-1.3499ptHeavy drinker2 (6.9)1 (3.3)Discharge medication, n (%)Aspirin29 (100)30 (100)1.000Statin1.000Rosuvastatin 20 mg a day29 (100)30 (100)Beta blocker0.617Carvedilol21 (72.4)22 (73.3)Nebivolol5 (17.2)7 (23.3)Angiotensin blockade25 (86.2)28 (93.3)0.635Calcium channel blocker1 (3.4)0 (0.0)0.986Proton pump inhibitor25 (86.2)26 (86.7)1.000Loop diuretic1 (3.4)2 (6.7)1.000Spironolactone1 (3.4)0 (0.0)0.492Nitrate4 (13.8)0 (0.0)0.112Trimetazidine2 (6.9)0 (0.0)0.457Procedural dataPre-PCI TIMI flow grade, n (%)0.672023 (79.3)22 (73.3)11 (3.4)2 (6.7)25 (17.2)6 (20.0)Post-PCI TIMI flow grade, n (%)1.00022 (6.9)2 (6.7)327 (93.1)28 (93.3)(n = 29)(n = 30)Multivessel disease, n (%)13 (44.8)16 (53.3)0.514Multivessel PCI, n (%)3 (10.3)3 (10.0)0.965Infarct-related artery, n (%)0.072Left anterior descending20 (69.0)19 (63.3)Left circumflex6 (20.7)7 (23.3)Right coronary3 (10.3)4 (13.3)Intervention method, n (%)0.112Drug-eluting stent26 (89.7)30 (100)Bioresorbable scaffold3 (10.3)0 (0.0)Number of stents1.1 ± 0.31.1 ± 0.30.400BMI, body mass index; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. Baseline characteristics according to type of P2Y12 inhibitor. BMI, body mass index; COPD, chronic obstructive pulmonary disease; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. Table 2Laboratory measurements according to type of P2Y12 inhibitor.Laboratory measurementsClopidogrel groupTicagrelor groupp value(n = 29)(n = 30)Baseline lab data: on-admissionWBC, x103/mm312.3 ± 3.811.0 ± 2.60.138Hb, g/dL14.9 ± 1.815.0 ± 1.50.763Platelet, x103/mm3262.8 ± 63.4255.4 ± 67.50.665GFR, ml/min/1.73 m2 (MDRD)88 ± 1885 ± 170.474Total cholesterol, mg/dL203.7 ± 49.2194.5 ± 52.40.487Triglyceride, mg/dL224.3 ± 147.0230.1 ± 183.00.893HDL-C, mg/dL42.3 ± 12.939.6 ± 10.20.380LDL-C, mg/dL141.0 ± 46.7133.1 ± 40.00.487VerifyNow, PRU242 ± 44241 ± 550.898NT-pro-BNP, pg/mL617 ± 461760 ± 7460.402LV ejection fraction, %53.0 ± 6.953.7 ± 6.20.684Pulse wave velocity, m/sec1.48 ± 0.231.43 ± 0.240.441Ankle-brachial index1.1 ± 0.11.1 ± 0.10.973Follow-up lab data: 6 monthsWBC, x103/mm38.2 ± 2.87.5 ± 2.00.328Hb, g/dL14.5 ± 1.414.5 ± 1.40.988Platelet, x103/mm3242.3 ± 61.6241.1 ± 58.50.939GFR, ml/min/1.73 m2 (MDRD)99 ± 2783 ± 130.005Total cholesterol, mg/dL135.0 ± 22.1117.6 ± 18.00.002Triglyceride, mg/dL170.3 ± 97.0151.0 ± 88.70.427HDL-C, mg/dL44.8 ± 13.543.4 ± 12.10.677LDL-C, mg/dL74.3 ± 20.858.7 ± 11.90.001VerifyNow, PRUa146 ± 5532 ± 67< 0.001NT-pro-BNP, pg/ml246 ± 449137 ± 1400.217LV ejection fraction, %55.3 ± 7.256.1 ± 5.80.635Pulse wave velocity, m/sec1.37 ± 0.181.36 ± 0.180.614Ankle-brachial index1.1 ± 0.11.1 ± 0.10.690EndoPAT(n = 18)(n = 18)RHI, %1.7 ± 0.41.9 ± 0.60.442aVerifyNow assay was evaluated at 1-month follow-up, whereas other lab measures were conducted at 6-month follow-up.Hb, hemoglobin; HDL-C, high-density lipoprotein cholesterol; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; MDRD, Modification of Diet in Renal Disease; NT-pro-BNP, N-terminal-pro-Brain Natriuretic Peptide; PRU, P2Y12 reaction units; RHI, reactive hyperemia index; WBC, white blood cell. Laboratory measurements according to type of P2Y12 inhibitor. VerifyNow assay was evaluated at 1-month follow-up, whereas other lab measures were conducted at 6-month follow-up. Hb, hemoglobin; HDL-C, high-density lipoprotein cholesterol; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; MDRD, Modification of Diet in Renal Disease; NT-pro-BNP, N-terminal-pro-Brain Natriuretic Peptide; PRU, P2Y12 reaction units; RHI, reactive hyperemia index; WBC, white blood cell. In the 6-month questionnaires (Table 3), patients receiving ticagrelor had significantly lower IIEF-5 scores than those receiving clopidogrel (9.7 ± 8.8 vs. 17.0 ± 7.8; p = 0.002). The ticagrelor group also had significantly lower scores across all five domains (all p values ≤ 0.015). At the 6-month follow-up, moderate-to-severe ED was more common among patients treated with ticagrelor than among those treated with clopidogrel (63.3% vs. 31.0%; p = 0.013). Bleeding events were predominantly minor: among the 32 patients who experienced at least one bleeding episode, 31 (96.9%) had BARC type 1 bleeding only, one (3.1%) had BARC type 2 bleeding, and none experienced BARC type 3–5 bleeding (Table 3). Table 3Questionnaires at 6 months: erectile dysfunction, bleeding and dyspnea according to type of P2Y12 inhibitor.Questionnaire itemClopidogrel groupTicagrelor groupp value(n = 29)(n = 30)ED category by IIEF-5, n(%)0.028No (22–25)9 (31.0)2 (6.7)Mild (17–21)10 (34.5)8 (26.7)Mild to moderate (12–16)1 (3.4)1 (3.3)Moderate (8–11)6 (20.7)6 (20.0)Severe (5–7)3 (10.3)13 (43.3)Moderate-to-severe ED, n (%)9 (31.0)19 (63.3)0.013IIEF-5 score17.0 ± 7.89.7 ± 8.80.002Erectile function3.4 ± 1.72.0 ± 1.90.004Orgasmic function3.4 ± 1.52.3 ± 1.80.015Sexual desire3.5 ± 1.61.9 ± 1.90.001Intercourse satisfaction3.3 ± 1.61.8 ± 1.90.001Overall satisfaction3.3 ± 1.61.7 ± 1.80.001Bleeding (BARC), n (%)12 (41.4)20 (66.7)0.051Type 112 (41.4)19 (63.3)Type 20 (0.0)1 (3.3)Type 30 (0.0)0 (0.0)Type 50 (0.0)0 (0.0)Dyspnea (mMRC), n (%)0.851Grade 021 (72.4)22 (73.3)Grade 18 (27.6)7 (23.3)Grade 20 (0.0)1 (3.3)Grade 30 (0.0)0 (0.0)Grade 40 (0.0)0 (0.0)BARC, Bleeding Academic Research Consortium; ED, erectile dysfunction; IIEF-5, International Index of Erectile Function-5; mMRC, modified Medical Research Council. Questionnaires at 6 months: erectile dysfunction, bleeding and dyspnea according to type of P2Y12 inhibitor. BARC, Bleeding Academic Research Consortium; ED, erectile dysfunction; IIEF-5, International Index of Erectile Function-5; mMRC, modified Medical Research Council. Bleeding events were more frequent in the ticagrelor vs. clopidogrel group, predominantly BARC type 1 (66.7% vs. 41.4%; p = 0.051). In contrast, dyspnoea incidence did not differ significantly between the groups (26.7% vs. 27.6%; p = 0.851). . ED classification: baseline characteristics, laboratory measurements, and questionnaires Baseline characteristics, including comorbidities and concomitant medications, were similar across ED categories, except for P2Y12 inhibitor type (Table 4). Patients with moderate-to-severe ED were more likely to receive ticagrelor than those with no-to-mild ED (67.9% vs. 35.5%; p = 0.026). Laboratory measurements on admission and at follow-up did not differ between the groups, except for the 1-month VerifyNow results (Table 5). Moderate-to-severe ED was significantly associated with a more potent antiplatelet effect (59.7 ± 76.8 vs. 113.2 ± 82.5 PRU; p = 0.013). In the 6-month questionnaires (Table 6), moderate-to-severe ED was significantly associated with bleeding episodes (71.5% vs. 41.5%; p = 0.046), whereas no association was observed with dyspnea (35.7% vs. 19.4%; p = 0.121). Table 4Baseline characteristics according to ED classification.CharacteristicsNo-to-mild ED (n = 31)Moderate-to-severe ED (n = 28)p valueAge, year old53.4 ± 6.752.4 ± 7.80.627Male, n (%)31 (100)28 (100)1.000BMI, kg/m225.6 ± 3.825.4 ± 2.70.755Killip class, n (%)0.341I18 (58.1)21 (75.0)II9 (29.0)4 (14.3)III4 (12.9)3 (10.7)Risk factors or past history, n (%)Diabetes mellitus4 (12.9)2 (7.1)0.764Hypertension10 (32.3)9 (32.1)1.000Dyslipidemia16 (51.6)13 (46.4)0.891Current smoking23 (74.2)19 (67.9)0.804Chronic kidney disease2 (6.5)1 (3.6)1.000Peripheral artery disease0 (0.0)1 (3.6)0.959Previous stroke1 (3.2)0 (0.0)1.000COPD0 (0.0)1 (3.6)0.959Alcohol consumption0.161Non-drinker14 (45.2)18 (64.3)Moderate drinker14 (45.2)10 (35.7)Heavy drinker3 (9.7)0 (0.0)Discharge medication, n (%)Aspirin31 (100)28 (100)1.000P2Y12 inhibitor0.026Clopidogrel20 (64.5)9 (32.1)Ticagrelor11 (35.5)19 (67.9)Statin1.000Rosuvastatin 20 mg a day31 (100)28 (100)Beta blocker0.904Carvedilol22 (71.0)21 (75.0)Nebivolol7 (22.6)5 (17.9)Angiotensin blockade29 (93.5)24 (85.7)0.574Calcium channel blocker0 (0.0)1 (3.6)0.959Proton pump inhibitor28 (90.3)23 (82.1)0.592Loop diuretic1 (3.2)2 (7.1)0.928Spironolactone1 (3.2)0 (0.0)1.000Nitrate3 (9.7)1 (3.6)0.680Trimetazidine0 (0.0)2 (7.1)0.427Procedural dataPre-PCI TIMI flow grade, n (%)0.789024 (77.4)21 (75.0)11 (3.2)2 (7.1)26 (19.4)5 (17.9)Post-PCI TIMI flow grade, n (%)0.53321 (3.2)3 (10.7)330 (96.8)25 (89.3)Multivessel disease, n (%)18 (58.1)11 (39.3)0.238Multivessel PCI, n (%)3 (9.7)2 (7.1)1.000Infarct-related artery, n (%)0.674Left anterior descending19 (61.3)14 (50.0)Left circumflex10 (32.3)12 (42.9)Right coronary2 (6.5)2 (7.1)Intervention method, n (%)1.000Drug-eluting stent29 (93.5)27 (96.4)Bioresorbable scaffold2 (6.5)1 (3.6)Number of stents1.1 ± 0.31.1 ± 0.30.733BMI, body mass index; COPD, chronic obstructive pulmonary disease; ED, erectile dysfunction; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. Baseline characteristics according to ED classification. BMI, body mass index; COPD, chronic obstructive pulmonary disease; ED, erectile dysfunction; PCI, percutaneous coronary intervention; TIMI, Thrombolysis in Myocardial Infarction. Table 5Laboratory measurements according to ED classification.Laboratory measurementsNo-to-mild EDModerate-to-severe EDp value(n = 31)(n = 28)Baseline lab data: on-admissionWBC, x103/mm311.6 ± 3.211.8 ± 3.50.775Hb, g/dL14.9 ± 1.915.0 ± 1.20.865Platelet, x103/mm3260.2 ± 60.7257.7 ± 70.70.882GFR, ml/min/1.73 m2 (MDRD)86.8 ± 18.386.6 ± 16.70.969Total cholesterol, mg/dL203.8 ± 58.0193.8 ± 41.40.452Triglyceride, mg/dL235.1 ± 180.5218.6 ± 148.50.705HDL-C, mg/dL39.5 ± 11.942.5 ± 11.20.333LDL-C, mg/dL144.8 ± 45.3128.4 ± 39.70.147VerifyNow, PRU241.0 ± 42.2241.7 ± 57.40.959NT-proBNP, pg/ml711.3 ± 597.1673.3 ± 666.30.824LV ejection fraction, %53.7 ± 7.153.0 ± 6.00.669Pulse wave velocity, m/sec1.47 ± 0.271.37 ± 0.230.14915.6-7.4,-1.3498ptAnkle-brachial index1.1 ± 0.11.1 ± 0.10.556Follow-up lab data: 6 monthsWBC, x103/mm37.9 ± 2.37.8 ± 2.60.965Hb, g/dL14.5 ± 1.414.5 ± 1.30.947Platelet, x103/mm3234.9 ± 48.1249.3 ± 70.20.368GFR, ml/min/1.73 m2 (MDRD)91.7 ± 24.589.5 ± 19.20.710Total cholesterol, mg/dL125.2 ± 21.5127.2 ± 22.50.721Triglyceride, mg/dL157.4 ± 76.7163.9 ± 108.80.788HDL-C, mg/dL42.5 ± 11.845.9 ± 13.70.303LDL-C, mg/dL67.3 ± 18.565.4 ± 18.70.687VerifyNow, PRUa113.2 ± 82.559.7 ± 76.80.013NT-proBNP, pg/ml231.2 ± 424.2143.9 ± 172.70.322LV ejection fraction, %56.2 ± 6.155.3 ± 7.00.614Pulse wave velocity, m/sec1.36 ± 0.181.29 ± 0.160.139Ankle-brachial index1.2 ± 0.11.1 ± 0.10.260EndoPAT(n = 23)(n = 13)RHI, %1.8 ± 0.51.8 ± 0.50.730aVerifyNow P2Y12 assay was evaluated at 1-month follow-up, whereas other lab measures were conducted at 6-month follow-up.Hb, hemoglobin; HDL-C, high-density lipoprotein cholesterol; ED, erectile dysfunction; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; MDRD, Modification of Diet in Renal Disease; PRU, P2Y12 reaction units; RHI, reactive hyperemia index; WBC, white blood cell. Laboratory measurements according to ED classification. VerifyNow P2Y12 assay was evaluated at 1-month follow-up, whereas other lab measures were conducted at 6-month follow-up. Hb, hemoglobin; HDL-C, high-density lipoprotein cholesterol; ED, erectile dysfunction; GFR, glomerular filtration rate; LDL-C, low-density lipoprotein cholesterol; LV, left ventricular; MDRD, Modification of Diet in Renal Disease; PRU, P2Y12 reaction units; RHI, reactive hyperemia index; WBC, white blood cell. Table 6Questionnaires at 6 months: erectile dysfunction, bleeding and dyspnea according to ED classification.Questionnaire itemNo-to-mild EDModerate-to-severe EDp value(n = 31)(n = 28)ED category by IIEF-5, n (%)< 0.001No (22–25)11 (35.5)0 (0.0)Mild (17–21)18 (58.1)0 (0.0)Mild to moderate (12–16)2 (6.5)0 (0.0)Moderate (8–11)0 (0.0)12 (42.9)Severe (5–7)0 (0.0)16 (57.1)IIEF-5 score21.0 ± 3.04.8 ± 4.6< 0.001Erectile function4.2 ± 0.71.0 ± 1.1< 0.001Orgasmic function4.2 ± 0.71.4 ± 1.3< 0.001Sexual desire4.3 ± 0.60.9 ± 1.0< 0.001Intercourse satisfaction4.2 ± 0.80.8 ± 0.9< 0.001Overall satisfaction4.1 ± 0.70.8 ± 1.0< 0.001Bleeding (BARC), n (%)0.046Type 113 (41.9)19 (67.9)Type 20 (0.0)1 (3.6)Type 30 (0.0)0 (0.0)Type 50 (0.0)0 (0.0)Dyspnea (mMRC), n (%)0.121Grade 025 (80.6)18 (64.3)Grade 16 (19.4)9 (32.1)Grade 20 (0.0)1 (3.6)Grade 30 (0.0)0 (0.0)Grade 40 (0.0)0 (0.0)BARC, Bleeding Academic Research Consortium; ED, erectile dysfunction; IIEF-5, International Index of Erectile Function-5; mMRC, modified Medical Research Council. Questionnaires at 6 months: erectile dysfunction, bleeding and dyspnea according to ED classification. BARC, Bleeding Academic Research Consortium; ED, erectile dysfunction; IIEF-5, International Index of Erectile Function-5; mMRC, modified Medical Research Council. . Association between antiplatelet effect and bleeding episode Platelet reactivity was significantly and inversely associated with the risk of bleeding during the follow-up period (per 10-PRU decrease: OR, 0.926; 95% CI, 0.866–0.990; p = 0.024). To assess the discriminatory ability of platelet reactivity for bleeding, we performed ROC curve analysis using PRU values. A PRU cutoff of ≤ 120 was identified as optimal and used to define the low platelet reactivity (LPR) phenotype; its discriminatory performance was modest and did not reach conventional statistical significance (sensitivity 55.6%, specificity 78.1%, AUC 0.638, 95% CI 0.491–0.786, p = 0.069) (Figure 2A). However, the LPR phenotype was significantly associated with bleeding risk (67.6% vs. 31.8%: OR, 4.464; 95% CI, 1.441–13.831; p = 0.008). The prevalence of the LPR phenotype was significantly higher in the ticagrelor group than in the clopidogrel group (90.0% vs. 34.5%; OR, 17.100; 95% CI, 4.144–70.565; p < 0.001) (Figure 2B). Association between antiplatelet effect and bleeding episodes: (A) ROC curve analysis (PRU cutoff for bleeding episodes) and (B) prevalence of LPR phenotype (clopidogrel vs. ticagrelor). AUC, area under the curve; CI, confidence interval; LPR, low platelet reactivity; OR, odds ratio; PRU, P2Y12 reaction unit; ROC, receiver operating characteristic. . Factors associated with moderate-to-severe ED P2Y12 inhibitor type, bleeding episodes, and PRU levels differed significantly across ED categories (Tables 4–6). Given the significant association between PRU levels and bleeding episodes, we assessed the combined contribution of P2Y12 inhibitor type and bleeding episodes to moderate-to-severe ED. In multivariable analysis, P2Y12 inhibitor type and bleeding episodes were jointly associated with the odds of moderate-to-severe ED (Table 7A). Compared with clopidogrel-treated patients without bleeding, ticagrelor-treated patients with bleeding had an approximately 7.2-fold higher odds of moderate-to-severe ED (95% CI, 1.683–30.804; p = 0.008). This association remained significant after adjustment for the LPR phenotype (OR, 5.625; 95% CI, 1.052–30.087; p = 0.044) (Table 7B), suggesting a potential association beyond ticagrelor's antiplatelet activity. Table 7Factors associated with moderate-to-severe ED at 6 months post-PCI.VariableOdds ratio95% CIp value(A) Model 1: P2Y12 inhibitor type plus bleeding episodes*Clopidogrel & no bleeding vs.0.034Clopidogrel & bleeding1.2000.245–5.8860.822Ticagrelor & no bleeding1.6000.310–8.2470.574Ticagrelor & bleeding7.2001.683–30.8040.008 (B) Model 2: Model 1 plus LPR phenotype * Clopidogrel & no bleeding vs.0.156Clopidogrel & bleeding1.1440.230–5.6960.869Ticagrelor & no bleeding1.3700.243–7.7230.721Ticagrelor & bleeding5.6251.052–30.0870.044LPR phenotype ( ≤ 120 PRU)1.4750.383–5.6820.572CI, confidence interval; ED, erectile dysfunction; LPR, low platelet reactivity; PCI, percutaneous coronary intervention; PRU, P2Y12 reaction unit. *The final models were intentionally kept parsimonious to reduce the risk of overfitting. Factors associated with moderate-to-severe ED at 6 months post-PCI. CI, confidence interval; ED, erectile dysfunction; LPR, low platelet reactivity; PCI, percutaneous coronary intervention; PRU, P2Y12 reaction unit. *The final models were intentionally kept parsimonious to reduce the risk of overfitting. Discussion This study provides novel insights into the association between P2Y12 inhibitor type and erectile dysfunction in patients with AMI. Key findings from STEMI patients undergoing primary PCI are summarized as below: (1) ED remained common despite contemporary procedural strategies and GDMT (81.4%); (2) bleeding episodes (predominantly BARC type 1) were frequently observed during 6 months of DAPT (41.4% in clopidogrel and 66.7% in ticagrelor); (3) vascular function measurements (eg, ABI, baPWV, and EndoPAT-RHI) did not differ after 6 months of ticagrelor or clopidogrel therapy; (4) ED severity did not differ according to concomitant CV medications, except for P2Y12 inhibitor type; (5) compared with clopidogrel, ticagrelor was associated with approximately 17-fold higher odds of the LPR phenotype, which was in turn associated with more frequent bleeding episodes; and (6) P2Y12 inhibitor type (ticagrelor vs. clopidogrel) and bleeding episodes were jointly associated with the odds of moderate-to-severe ED. Compared with clopidogrel, ticagrelor provided more potent P2Y12 inhibition and was associated with a higher prevalence of the LPR phenotype and more frequent bleeding episodes. In addition, extraplatelet P2Y12 inhibition by ticagrelor in other tissues—potentially including the penile vasculature—may be associated with deterioration in erectile function; however, this remains a hypothesis and is not directly supported by the present data (Figure 3). Proposed conceptual framework: association between P2Y12 inhibitor type, bleeding episodes, and erectile dysfunction. LPR: low platelet reactivity, PRU: P2Y12 reaction unit. The effects of antiplatelet therapy on erectile function remain poorly defined, particularly for P2Y12 inhibitors in patients with AMI. Limited prior data suggest a possible association between antiplatelet therapy and sexual dysfunction, although evidence remains inconsistent (12, 13). In the present study, ticagrelor was associated with a significantly higher prevalence of moderate-to-severe ED than clopidogrel, suggesting a potential link between more potent platelet inhibition and impaired erectile function. The purinergic P2Y12 receptor is expressed predominantly on platelets and megakaryocytes, where ADP–P2Y12 signaling sustains platelet activation and aggregation. Ticagrelor provides more potent inhibition of the platelet P2Y12 receptor than clopidogrel, leading to lower platelet reactivity and a higher incidence of bleeding events—predominantly nuisance bleeding in this study. In AMI patients treated with DAPT, nuisance bleeding is common and independently associated with worse quality of life, including pain, discomfort, dyspnoea, anxiety, and depression (14). Anxiety, depression, fear of recurrent cardiac events, and concerns about resuming sexual activity were not assessed and may represent important unmeasured mediators or confounders. Previous studies have shown that psychological distress after AMI is strongly associated with impaired sexual function and may influence ED more profoundly than nuisance bleeding alone (15). Thus, psychosocial factors—potentially intertwined with bleeding events and treatment awareness—may account for a substantial proportion of the observed association rather than a direct effect of ticagrelor or potent platelet inhibition. Accordingly, although our findings suggest a possible association between ticagrelor treatment and erectile dysfunction, the proposed pathway should be regarded as one of several plausible interpretations rather than a demonstrated biological mechanism. The mechanism underlying the observed association remains uncertain. Bleeding-related effects on quality of life, unmeasured psychosocial factors, and ticagrelor-specific purinergic or adenosine-mediated effects are plausible pathways; however, none were evaluated in this study, and their relevance to human erectile function remains unknown (4, 5, 16–18). These mechanisms should therefore be considered hypothesis-generating and require validation in prospective mechanistic studies. After PCI for AMI, DAPT with a potent P2Y12 inhibitor (e.g., prasugrel or ticagrelor) is the standard of care for potent platelet inhibition and thrombotic event reduction, especially during the acute phase. During the stable phase, clinical relevance of nuisance bleeding extends well beyond the bleeding event itself. It is among the most frequent complications of DAPT with a potent P2Y12 inhibitor and is a major driver of poor treatment adherence (19, 20). In addition, repeated nuisance bleeding may serve as an early clinical signal of an individual patient's heightened bleeding propensity and can prompt reassessment for optimal antiplatelet effect (21). Therefore, growing interest exists in de-escalation strategies during the stable phase to reduce clinically significant bleeding risk without concern for ischaemic events (22, 23). To this end, early aspirin discontinuation and reduced-dose ticagrelor-based regimens (e.g., 60 mg ticagrelor) may be considered in selected patients, but further evidence is needed before these approaches can be adopted as routine strategies (24). Although these findings may encourage greater attention to sexual health during follow-up, they should not be interpreted as supporting changes in antiplatelet therapy solely to improve erectile function. The current study highlights the need to address both CV and quality-of-life domains in patients with STEMI, supporting tailored antiplatelet approaches that incorporate individual patient needs. However, given the observational nature of this substudy, no causal or mechanistic inferences can be drawn from the present findings. This study has several limitations. First, although treatment allocation was based on the multicenter randomized trial, this erectile dysfunction substudy was conducted at a single participating center and included a relatively small sample. Therefore, selection bias cannot be excluded, and the generalizability of the findings to broader STEMI populations and other clinical settings may be limited. Second, baseline IIEF-5 scores were unavailable because emergent primary PCI precluded pretreatment assessment. Thus, we could not distinguish pre-existing from incident ED or evaluate longitudinal changes, limiting causal inference. Furthermore, unmeasured factors—including prior ED, PDE5 inhibitor use, testosterone status, psychological factors, sexual activity, marital status, and partner availability—may have influenced erectile function independently of antiplatelet therapy. Third, a temporal mismatch existed between the timing of platelet reactivity assessment (at 1-month follow-up) and that of erectile dysfunction (at 6-month follow-up). Nevertheless, platelet reactivity measured at 1 month is likely to reflect the steady-state antiplatelet effect established after PCI in patients with STEMI. Fourth, significant differences in follow-up LDL-C and eGFR levels were observed between treatment groups. The difference in LDL-C levels achieved at 6 months was more likely attributable to differences in baseline LDL-C and individual responses to the same dose of rosuvastatin than to differential medication adherence. Similarly, the lower follow-up eGFR in the ticagrelor group is unlikely to reflect poorer adherence. Fifth, the limited sample size restricted multivariable adjustment and model complexity. Although parsimonious models were used to minimize overfitting, model instability, sparse-data bias, and estimation uncertainty remain possible, as reflected by the wide confidence intervals. The odds ratios should therefore be interpreted primarily as indicating the presence and direction of associations rather than their precise magnitude. Sixth, no mechanistic biomarkers or penile vascular assessments were performed; therefore, the proposed biological mechanisms linking ticagrelor treatment to erectile function remain speculative. Seventh, nearly all bleeding episodes were limited to BARC type 1 nuisance bleeding. Although minor by definition, nuisance bleeding may adversely affect quality of life, undermine confidence in treatment, and contribute to nonadherence or premature antiplatelet discontinuation. However, its cumulative burden, effects on adherence and health status, and subsequent treatment modifications were not systematically assessed. Finally, the analysis focused on erectile function at 6 months and did not assess longer-term outcomes; therefore, whether any observed associations are transient or persistent remains unclear. Conclusions After primary PCI in male patients with STEMI, moderate-to-severe ED and bleeding episodes were common during DAPT. P2Y12 inhibitor type (ticagrelor vs. clopidogrel) and bleeding episodes were associated with lower erectile function scores and a higher prevalence of moderate-to-severe ED at 6 months. Given the exploratory nature of this substudy and the lack of baseline erectile function assessment, these findings should be considered hypothesis-generating and warrant confirmation in larger prospective studies.